Pharvaris NV (PHVS) reported its Q3 2025 financial results, delivering earnings per share (EPS) of $0.00, which exceeded Wall Street's consensus estimate of $-0.67 by $0.67. Revenue for the quarter matched expectations at $0.0 billion.
The company is a clinical-stage firm focused on developing oral bradykinin B2-receptor antagonists to treat hereditary angioedema (HAE) attacks. Its key product, Deucrictibant, is being developed for both on-demand and prophylactic treatment. Pharvaris is headquartered in Leiden, Netherlands, and employs 108 full-time staff. The firm went public on February 5, 2021, and currently holds a market capitalization of $1.4 billion.
Pharvaris will host its earnings conference call after market close to discuss these results and provide further insights into its business performance. Upcoming earnings reports are scheduled for May 10, 2026, with an EPS estimate of $-0.65, and August 9, 2026, with an EPS estimate of $-0.67.
This earnings report offers a glimpse into Pharvaris NV's operational performance and financial health, indicating that the company's results align with market forecasts. Investors are encouraged to review the complete earnings release and management commentary for a thorough understanding of the quarter's performance and future outlook.